01 — At a Glance
A Pharma Company Dismantling Itself, Very Slowly
- 52-Week High / Low₹5,993 / ₹3,701
- TTM Revenue₹2,482 Cr
- TTM PAT₹854 Cr
- TTM EPS₹186.57
- Q3 FY26 EPS (Dec 2025)₹31.00
- Book Value₹841
- Price to Book5.75x
- Dividend Yield0.73%
- Debt / Equity0.01x
- 3-Year Return8.69%
The Brutal Summary: Pfizer India just posted Q3 PAT of ₹142 crore on ₹645 crore revenue (+19.9% YoY sales, +43% profit growth YoY). OPM at 35%, PAT margin at 22%. Textbook execution. Except the parent company decided to wholesale four of their bestselling brands to Cipla for literally nothing — zero upfront consideration — and still the stock trades at 29x P/E. Something doesn’t add up. Either the market doesn’t understand the portfolio drain, or Wall Street paid a heavy price for exiting India somewhere else.
02 — Introduction
Pfizer India: The Slow Motion Train Wreck Nobody’s Watching
Let me set the scene. Pfizer is a $70+ billion global pharma and vaccine juggernaut. Vaccines, oncology, cardiology, neuroscience, immunology — they have products that save lives and make shareholders very comfortable. In India, they’re the 3rd largest multinational pharma company by market position.
So naturally, in December 2025, Pfizer decided to hand their four biggest Indian revenue-generators to Cipla — a domestic competitor — on an exclusive five-year marketing agreement for a flat zero rupees upfront.
The brands? Corex DX (dry cough leader with 15% market share), Corex LS, Dolonex (pain relief), and Neksium (stomach acid). All four account for a meaningful chunk of Pfizer India’s portfolio revenue. And now Cipla gets to sell them. Pfizer gets… workforce reductions. And the stock somehow still justifies a 29x P/E valuation. The premium on what, exactly — the privilege of watching your business get sold?
But Q3 results landed with a thud: ₹645 crore in quarterly sales, ₹182 crore in PAT. Profitable. Growing. And being systematically dismantled by the parent’s “optimization” playbook. This is the story of a multinational pharma that’s decided to trim India operations while its margins stay thick and its ROCE stays respectable. It’s neither a buy nor a disaster. It’s a slow fade.
The Real Headline: Pfizer granted Cipla exclusive India marketing rights for four major brands (Dec 19, 2025) with workforce reductions announced. Aditi Mehta (Category Lead – Vaccines) resigned Jan 2, 2026. New Category Lead (Nilesh Pendse) appointed Feb 1, 2026. Management is clearly in transition.
03 — Business Model: Pills, Potions, and a Parent Selling the Cabinet
What They Sell vs. What They’re Keeping
Pfizer India manufactures, markets, and distributes pharmaceutical products across five major therapeutic areas: vaccines, internal medicine, hospital business, neuroscience, and inflammation/immunology. Revenue sits at ₹2,482 crore (TTM), with a portfolio reaching 2 lakh+ healthcare providers, 1,800 hospitals, and 2.5 lakh+ retail pharmacies.
The Goa manufacturing facility produces 3.6 billion tablets annually — an absolute beast for internal medicine portfolio manufacturing. Contract manufacturers add another 1.94 billion units. About 70% of the business is manufactured locally, and 75% of raw materials sourced locally, which is decent for a multinational.
But here’s the kicker: the revenue base that’s being kept versus the four brands being handed over suggests management believes the future is vaccines and specialty care — higher margin, lower competitive chaos. Corex (dry cough), Dolonex (generics pain market), and Neksium (acid reflux commodity) are being treated as “legacy Indian OTC franchises.” Translation: “We can’t grow these fast enough at global P/E multiples, so let someone else milk them.”
Vaccine Market Share52%Prevenar 13 Units
Corex Mkt Share15%Now To Cipla
Duty50 Vaccinated1.9L+Adult Initiative
The Vaccine Thesis: Pfizer owns 52% of India’s private pneumococcal vaccine market (Prevenar 13). This is the crown jewel — high-margin, growing, OEM-approved, and globally relevant. Duty50 (adult vaccination initiative) has vaccinated 190,000+ people in partnerships with 20+ corporations. This is what Pfizer wants to own. Corex? They want it gone from the balance sheet.
💬 Here’s the real question: If Pfizer’s Indian OTC brands are so great, why is the stock not crashing post-announcement? Or does Wall Street simply not care about India’s pharma generic-ization anymore?
04 — Financials Overview
Q3 FY26: The Last Dance Before Restructuring?
Result type: Quarterly Results (9M period) | Q3 EPS: ₹31.00 | Annualised EPS (Q3×4): ₹124 | TTM EPS: ₹186.57
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 645 | 538 | 642 | +19.9% | +0.5% |
| Operating Profit | 228 | 146 | 230 | +56.2% | -0.9% |
| OPM % | 35% | 27% | 36% | +800 bps | -100 bps |
| PAT | 142 | 128 | 189 | +11.0% | -24.9% |
| EPS (₹) | 31.00 | 27.89 | 41.32 | +11.1% | -24.9% |
The PAT Paradox: Revenue up 19.9% YoY, but PAT up only 11%. Why? Margin compression. Q3 FY25 had some one-time tailwinds (OPM 27%, but PAT benefited from exceptional items). More importantly, the guidance on portfolio divestiture and workforce reductions means one-time costs are probably already baked into Q3 numbers. That ₹182 crore PAT in the prior comparable quarter included the benefit of the exceptional items that lower quarters didn’t. Net-net: organic operational performance is solid, but the balance sheet gets whacked by restructuring charges going forward.
05 — Valuation: Fair Value Range
What’s A Pharma Company Worth When It’s Exiting Markets?
Join 10,000+ investors who read this every week.
